| ★ |  Imaging in Relapsing Polychondritis (RP) | | 171 | — | |
| 5 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 89 |
| 9 |  IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 88 |
| 7 |  ERN ReCONNET: the New 2026 Webinar Series | | 630 | — | 88 |
| 12 |  Recent advances in the treatment of inflammatory myopathies | | 618 | — | 88 |
| 1 |  Steroids in Relapsing Polychondritis | | 474 | — | 93 |
| 20 |  CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 87 |
| 18 |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | 87 |
| 2 |  Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 93 |
| 8 |  Why morning joint stiffness and swelling in rheumatic diseases? | | 398 | — | 88 |
| 16 |  How to explain the antiphospholipid profile to my patients? | | 300 | — | 87 |
| 15 |  Microvascular Involvement in Antiphospholipid Syndrome (APS) | | 264 | — | 87 |
| 17 |  Pulmonary Function Tests: A Practical Guide for Rheumatologists | | 253 | — | 87 |
| 13 |  The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | 88 |
| 14 |  Everything you always wanted to know about Ehlers-Danlos Syndromes (EDS) – Part two | | 151 | — | 87 |
| 11 |  Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 88 |
| 6 |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 89 |
| 10 |  Pregnancy in undifferentiated connective tissue disease (UCTD) | | 72 | — | 88 |
| 4 |  Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 90 |
| 19 |  ARTRITIS REUMATOIDE (Segunda parte) | | 52 | Colombia | 87 |
| 3 |  Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 90 |